US Pharma MarketingSionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.
Sionna cystic fibrosis drug fails key trial, removing threat to Vertex
Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.
Source: BioPharma Dive